In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zebra Biologics Inc.

Latest From Zebra Biologics Inc.

Keeping Track: AZ’s Busy Oncology Biz, Phathom’s Voquezna Approval, And A Trio Of Complete Response Letters

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Could The US FDA Set Clinical Trial Diversity Minimums?

Oncology Center of Excellence Director Richard Pazdur asked whether the FDA should have more conversations with sponsors about site selection and percentages of US participants.

Clinical Trials Diversity & Inclusion

April US FDA Approval Decisions To Cover Cardiomyopathy, CNS And China-Developed Cancer Drugs

Five novel agents have user fee goal dates in the coming month, the Pink Sheet’s US FDA Performance Tracker shows.

US FDA Performance Tracker Cancer

Broader Horizons For Advanced Biotech In 2022: New Targets, Settings For IO, Cell And Gene Therapy

US FDA’s user fee goal calendar for 2022 already contains 45 applications for novel agents featuring a wide array of biologics, from cell therapy in cancer and hematology to bispecifics and new immuno-oncology targets that could move the field beyond PD-1/L1.

Pink Sheet Perspectives US FDA Performance Tracker
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register